Welcome to our dedicated page for 2seventy bio news (Ticker: TSVT), a resource for investors and traders seeking the latest updates and insights on 2seventy bio stock.
2seventy bio, Inc. (TSVT) is a pioneering immuno-oncology cell therapy company committed to disrupting the cancer treatment landscape. The name '2seventy bio' reflects the speed of translating human thought into action—270 miles per hour—emphasizing the company’s focus on time and precision. The company leverages its in-depth understanding of cancer cell metabolism, genomics, and the immune response to tumor cells to develop advanced cellular therapies.
Core Business: 2seventy bio specializes in the research, development, and commercialization of transformative cancer treatments. By focusing on cellular therapies that are designed to 'think' smarter and faster than cancer, the company aims to provide innovative solutions for people living with cancer. These therapies are developed with the goal of optimizing the body's immune response to target and eliminate tumor cells effectively.
Recent Achievements and Current Projects: The company has recently entered into a significant partnership with Bristol Myers Squibb, highlighting its cutting-edge research and potential in the oncology space. Current projects at 2seventy bio include the development of new classes of cellular therapies aimed at enhancing patient outcomes and pushing the boundaries of what is possible in cancer treatment.
Financial Condition and Partnerships: Operating in a single segment focused on cancer treatments, 2seventy bio has shown strong financial health backed by strategic partnerships, such as the one with Bristol Myers Squibb. These collaborations not only provide financial stability but also accelerate the company's research and development efforts.
Products: 2seventy bio's product pipeline includes several promising candidates in various stages of development. These products are designed to offer new, effective treatment options for cancer patients, with a focus on maximizing the immune system’s ability to fight cancer.
Overall, 2seventy bio, Inc. is at the forefront of cancer therapy innovation, leveraging advanced scientific knowledge and strategic partnerships to drive its mission forward. The company's dedication to developing therapies that work faster and smarter than cancer underscores its commitment to improving the lives of those affected by this devastating disease.
2seventy bio, Inc. (NASDAQ: TSVT), a leader in immuno-oncology cell therapy, announced the participation of its management team in two upcoming investor conferences. The conferences are the 17th Annual Citi BioPharma Conference on September 7, 2022, in Boston, and the 2022 Morgan Stanley Global Healthcare Conference on September 14, 2022, in New York. Live webcasts will be available on the company’s website, with replays archived for 30 days. 2seventy bio focuses on developing innovative therapies for cancer treatment.
2seventy bio, Inc. (TSVT) reported $72 million in U.S. commercial revenue from ABECMA for Q2 2022, tracking towards the upper end of its $250-$300 million revenue guidance. Their KarMMa-3 trial demonstrated a significant improvement in progression-free survival for relapsed and refractory multiple myeloma patients. The company ended the quarter with $399 million in cash and marketable securities, and has revised its net cash spend guidance for 2022 to $245-$265 million. They foresee a cash runway extending into 2025.
Bristol Myers Squibb (NYSE: BMY) and 2seventy bio (NASDAQ: TSVT) announced positive topline results from the Phase 3 KarMMa-3 study, evaluating Abecma (idecabtagene vicleucel) in relapsed and refractory multiple myeloma. The trial met its primary endpoint, showing statistically significant improvement in progression-free survival versus standard treatments. Key secondary endpoints, including overall response rate, also showed improvement. No new safety signals were reported, confirming Abecma's well-established safety profile.
2seventy bio, Inc. (NASDAQ: TSVT) has announced participation in two key investor conferences. The first is the Wedbush PacGrow Healthcare Conference on August 10, 2022, at 1:10 PM ET, where they will join a panel discussion titled “A View to a Kill(er Cell) – Part 1.” The second event is the 42nd Annual Canaccord Genuity Growth Conference on August 11, 2022, at 2:30 PM ET in Boston, MA. Live webcasts will be available on 2seventy bio’s website, with replays archived for 30 days post-event.
2seventy bio, Inc. (NASDAQ: TSVT) announced its participation in the upcoming Goldman Sachs 43rd Annual Global Healthcare Conference. The event will take place on June 14, 2022, at 3:20 pm PT in Rancho Palos Verdes, CA. A live webcast will be available through the Investors and Media section of the company’s website, with an archived replay accessible for 30 days post-event. 2seventy bio is committed to pioneering cell therapies to enhance cancer treatment and focuses on delivering innovative therapies aimed at various hematologic malignancies and solid tumors.
2seventy bio reported first-quarter 2022 results, achieving $56 million in U.S. commercial revenue from ABECMA. The company remains on track to meet its revenue guidance of $250-$300 million for the year. The firm ended the quarter with $452.5 million in cash, projecting a runway into 2025. Key milestones include the enrollment of first patients in vital clinical studies for SC-DARIC33 and bbT369, with potential advancements in treatment for AML and B-NHL. The company reported a net loss of $85.7 million, reflecting ongoing investments in its operations.
2seventy bio (NASDAQ: TSVT) announced promising preclinical data for bbT369, a novel CAR T cell therapy targeting CD79a and CD20, showing enhanced efficacy against B cell non-Hodgkin lymphoma (B-NHL). bbT369 aims to address limitations of existing CAR T therapies by overcoming known mechanisms of treatment failure. Currently, the CRC-403 Phase 1/2 study is enrolling patients to assess its safety and efficacy, with initial results expected in 2022. This innovative approach could offer new hope for patients with relapsed or refractory B-NHL.
2seventy bio (Nasdaq: TSVT) will present at the CG Horizons in Oncology Virtual Conference on April 14, 2022, at 1:30 PM ET. The focus will be on new approaches to attacking AML. Live webcasts of the presentations will be accessible in the Investors and Media section of the company's website, with replays available for 30 days afterward. 2seventy bio aims to revolutionize cancer therapies through innovative cell treatments, emphasizing speed and efficacy in research and development.
2seventy bio (Nasdaq: TSVT) closed a $170 million private placement and reported 2021 financial results, with ABECMA generating $158 million in U.S. revenue. The company anticipates 2022 U.S. ABECMA revenues of $250-$300 million, tracking towards the high end due to strong patient demand. Cost reduction measures decreased net cash spend guidance to $190-$220 million for 2022, extending cash runway into 2025.
Positive developments include increased ABECMA manufacturing capacity planned for 2022, and key management appointments to drive growth.
2seventy bio, Inc. (NASDAQ: TSVT) has announced a private placement sale of approximately 13.9 million shares at $12.20 per share, raising around
FAQ
What is the current stock price of 2seventy bio (TSVT)?
What is the market cap of 2seventy bio (TSVT)?
What is the main focus of 2seventy bio, Inc.?
What inspired the name '2seventy bio'?
What kind of therapies does 2seventy bio develop?
Who are 2seventy bio's strategic partners?
How does 2seventy bio leverage its understanding of cancer?
What recent achievements has 2seventy bio made?
What is the financial condition of 2seventy bio?
What are the current projects at 2seventy bio?
What is the company's approach to cancer therapy?
What is the core business segment of 2seventy bio?
